Latest Headlines

  1. Skyhawk Therapeutics Announces Strategic Collaboration With Merck KGaA, Darmstadt, Germany To Discover Novel RNA-Targeting Small Molecules For Neurological Disorders 8/18/2025

    Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

  2. Researchers Glimpse The Inner Workings Of Protein Language Models 8/18/2025

    Within the past few years, models that can predict the structure or function of proteins have been widely used for a variety of biological applications, such as identifying drug targets and designing new therapeutic antibodies.

  3. SwRI Develops Chemistry LLM Called GAMES For Faster Drug Discovery 8/14/2025

    Southwest Research Institute scientists and engineers have developed a custom large language model (LLM) to accelerate drug design and discovery.

  4. Immunotherapy Drug Eliminates Aggressive Cancers In Clinical Trial 8/14/2025

    Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise—and induced great disappointment. While effective at activating the immune system to kill cancer cells in animal models, the drugs had limited impact on patients in clinical trials and caused dangerously systemic inflammatory responses, low platelet counts, and liver toxicity, among other adverse reactions—even at a low dose.

  5. Polaris Quantum Biotech Unveils QuADD: Next-Generation Quantum-AI Drug Discovery Platform - Beta Testers Wanted 8/12/2025

    Polaris Quantum Biotech (PolarisQB), a leader in quantum-powered life science solutions, today announced the official launch of QuADD (Quantum-Aided Drug Design), the world’s first SaaS platform harnessing quantum computing and artificial intelligence to revolutionize drug discovery.

  6. KAIST Develops AI That Automatically Designs Optimal Drug Candidates For Cancer-Targeting Mutations 8/12/2025

    Traditional drug development methods involve identifying a target protin (e.g., a cancer cell receptor) that causes disease, and then searching through countless molecular candidates (potential drugs) that could bind to that protein and block its function.

  7. Bayer And Kumquat Biosciences Enter Global Exclusive License And Collaboration In Precision Oncology 8/12/2025

    Bayer and Kumquat Biosciences Inc., a clinical-stage biotech company founded by pioneers of the KRAS pathway, today announced that they have entered into an exclusive global license and collaboration to develop and commercialize Kumquat's KRAS G12D inhibitor.

  8. HopeAI Joins Mayo Clinic Platform To Transform The Future Of Drug Development With AI 8/12/2025

    HopeAI, an emerging leader in applying artificial intelligence (AI) to accelerate new drug development, has officially joined the prestigious Mayo Clinic Platform Accelerate program.

  9. Garden Launches BLOOM To Make AI Drug Design IP-Aware In Real Time 8/11/2025

    Garden today announced BLOOM (Branching Lookup Optimized for Organic Molecules), a Markush structure search engine that gives AI drug-design teams near-instant verification of small-molecule IP landscapes, so researchers can iterate on candidates with legal certainty built into the loop.

  10. AMI Pharm Advances AYP-101 To Phase 3, Paving The Way For A New Era In Fat-Reduction Injectable Drugs 8/11/2025

    AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin").